TRANS-
FORMATIVE
Technologies
TRANS-
FORMATIVE
Technologies
Transformation. Unlocked.
DynamX® Drug Eluting Coronary Bioadaptor System
A significant innovation in the treatment of coronary artery disease. The future of vascular intervention won’t just evolve, it will adapt.
Restore
Intervene, don’t interfere.
First step in any intervention is restoring blood flow. And, with DynamX you may achieve significant acute lumen gain1 without compromising the ability for the vessel to naturally heal.
Release
Unlock the rush of freedom.
After 6 months, DynamX is designed to unlock itself and release the vessel to pulsate more freely and respond to every heartbeat, potentially increasing vital blood flow.Return
Arrive at a more natural state.
DynamX is designed to provide continuing dynamic support while the vessel returns to its natural physiology, motion and function, freeing it to adapt and maintain optimal lumen size.BIOADAPTOR RCT
In a large, randomized, controlled trial comparing the bioadaptor to a leading drug eluting stent (DES), DynamX demonstrated significant improvement in vessel physiology such as in-device pulsatility and lower late lumen loss, reflecting its unique mechanism of action.1*Caution: The DynamX Sirolimus Eluting Coronary Bioadaptor System is an investigational device. Limited by Federal (or United States) law to investigational use.
Potency where it’s needed most
Site-Specific Antithrombotic Therapy (TRx)
TRx is the world’s first triple-drug site-specific antithrombotic therapy using two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor, sirolimus. The therapy is designed to address challenges associated with percutaneous coronary intervention (PCI), including management of ischemic and bleeding risk due to use of systemic oral antithrombotic medications.
Harnessing the power of many
LithiX™ Hertz Contact Lithotripsy Catheter
Leveraging the power of physics and mechanics, the LithiX Hertz Contact Lithotripsy (HC-IVL) Catheter is designed to effectively fragment calcium without the need for capital equipment or disrupting standard PCI procedure workflow.
Using multiple discrete stress points to fracture calcium the system is designed to effectively treat concentric and eccentric calcified lesions.
References
- Saito S, et al. First randomized controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting stent in patients with de novo coronary artery lesions: 12-month clinical and imaging data from the multi-centre, international, BIOADAPTOR-RCT. eClinicalMedicine, The Lancet. 2023
PMN 2138 Rev A